This is to inform you that Outcome of the Board Meeting of the Company held on Friday 23rd May, 2025 in accordance with SEBl (Listing Obligations and Disclosures Requirements) Regulations, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.6 pts less than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biogen Pharmachem Industries Ltd (formerly Sun Techno Overseas Ltd) approved its audited financial results for FY ended March 31, 2025 on May 23, 2025. Revenue from operations fell sharply to Rs. 83.84 lakhs from Rs. 238.15 lakhs in FY24, a decline of nearly 65%. Total expenses more than doubled to Rs. 113.11 lakhs, pushing the company into a net loss of Rs. 29.27 lakhs versus a profit of Rs. 193.07 lakhs in the previous year. Operating cash flow turned negative at Rs. (109.10) lakhs compared to a positive Rs. 196.59 lakhs in FY24. On the positive side, the company raised Rs. 3,570 lakhs through a share issue, lifting other equity from negative Rs. 873.99 lakhs to positive Rs. 2,666.74 lakhs. The statutory auditor issued an unmodified (clean) opinion on the results.
Operationally the year was weak, with collapsing revenues, a swing to loss, and negative operating cash flow, which is a negative signal for shareholders. However, the large equity infusion has cleaned up the balance sheet and the clean audit opinion removes any immediate governance red flags. This remains a small, thinly-traded company with highly volatile earnings, making it a high-risk investment despite the strengthened net worth.